# Artiva Biotherapeutics, Inc. (ARTV) · Edgar & Edgarette company card

> Artiva Biotherapeutics (ARTV) saw revenue fall 100% in FY2025 to $0 million, operating margin null against a -15.8% median for biological products, (no diagnostic substances), equity 84.0% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1817241 · fiscal year ended 2025-12-31 · 3 audited years read · [page](https://www.pops4.com/boards/company/ARTV) · [JSON](https://www.pops4.com/boards/company/ARTV.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | -100.0% |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -26805.6%) |
| Net margin | -Infinity% |
| Operating cash flow | −$77M |
| Capital spending | $3M |
| Free cash flow | −$79M |
| Cash | $27M |
| Long-term debt | — |
| Total assets | $131M |
| Total equity | $110M |
| Equity ÷ assets | 84.0% |
| Return on equity | -76.3% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -2.34 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Old boat · three warning signs · filed restructuring or exit costs in the last 12 months; operating cash flow was negative (-$76.8M in FY2025); operating loss: a margin of -Infinity% in FY2025

## Edgarette's reading

Exposure: revenue $0K (FY2025). Experience: revenue down 100.0% on the year; operating margin null, down from -26805.6%. Soundness: equity 84.0% of assets, return on equity -76.3%. Credibility: 3 audited years, moderate weight. Range: 80% of past cases like this landed between $0K and $0K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin null against a -15.8% median; growth -100.0% against 21.4%.

Range logged 2026-09-20, receipt 4203f9dd5555fb46, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 2.05 Restructuring or exit costs: 1, latest 2026-10-27 ([filing](https://www.sec.gov/Archives/edgar/data/1817241/000119312526432806/0001193125-26-432806-index.htm))
- Item 5.02 Director or officer change: 5, latest 2026-09-11 ([filing](https://www.sec.gov/Archives/edgar/data/1817241/000119312526389308/0001193125-26-389308-index.htm))

## Recent filings

- 8-K · filed 2026-10-27 · 2.02 Results of Operations and Financial Condition; 2.05 Costs Associated with Exit or Disposal Activities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1817241/000119312526432806/0001193125-26-432806-index.htm)
- 8-K · filed 2026-09-11 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1817241/000119312526389308/0001193125-26-389308-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1817241/000119312526338029/0001193125-26-338029-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1817241/000119312526337986/0001193125-26-337986-index.htm)
- DEF 14A · filed 2026-08-03 · [filing](https://www.sec.gov/Archives/edgar/data/1817241/000119312526330563/0001193125-26-330563-index.htm)
- 8-K · filed 2026-07-22 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1817241/000119312526312560/0001193125-26-312560-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001817241.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1817241

## Cite

POPS4, Edgar & Edgarette: Artiva Biotherapeutics, Inc. (ARTV) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/ARTV. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.